ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
18.05
+1.10 (6.46%)
At close: Aug 13, 2025, 4:00 PM
18.02
-0.03 (-0.14%)
After-hours: Aug 13, 2025, 4:02 PM EDT

ArriVent BioPharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-136.79-80.49-69.33-36.91-68.81
Asset Writedown & Restructuring Costs
----57.21
Stock-Based Compensation
7.43.210.90.420.07
Change in Accounts Payable
0.25-0.751.382.80.39
Change in Other Net Operating Assets
2.717.8211.22-9.95-5.65
Operating Cash Flow
-126.63-70.21-55.84-43.63-16.78
Sale (Purchase) of Intangibles
-----53.33
Investment in Securities
-141.73-192.47---
Investing Cash Flow
-141.73-192.47---53.33
Total Debt Issued
----0.27
Total Debt Repaid
-----0.27
Issuance of Common Stock
82.81186.580.350.020
Other Financing Activities
-0.35--2.41--
Financing Cash Flow
82.46186.5842.86169.72119.82
Net Cash Flow
-185.9-76.1-12.98126.0949.71
Levered Free Cash Flow
-57.34-48.64-32.8-29.81-
Unlevered Free Cash Flow
-57.34-48.64-32.8-29.81-
Change in Working Capital
2.957.0712.6-7.15-5.25
Updated Aug 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q